<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.93035</article-id><article-id pub-id-type="publisher-id">ACM-29151</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190300000_53312232.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  原发性肝脏神经内分泌肿瘤的诊断和治疗进展
  Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>梦霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>启勇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>慜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>树森</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>浙江大学医学院附属第一医院肝胆胰外科，浙江 杭州</addr-line></aff><aff id="aff3"><addr-line>树兰(杭州)医院肝胆胰外科，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>02</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>225</fpage><lpage>234</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    原发性肝脏神经内分泌肿瘤(Primary hepatic neuroendocrine neoplasms, PHNENs)特指原发于肝脏的一组能够分泌生物活性胺和多肽类激素的异质性肿瘤，临床罕见，仅占所有NENs的0.3%~4.0%。大部分PHNENs的临床症状和影像学表现缺乏特异性，早期诊断困难，与转移性NENs难以鉴别。手术是治疗的首选，也是唯一可以根治的方法。对于不可切除的PHNENs，肝脏局部治疗有射频和肝动脉栓塞，系统治疗方法主要包括生长抑素类似物的生物治疗，哺乳动物雷帕霉素靶蛋白和酪氨酸激酶抑制剂的靶向治疗，肽受体放射性核素疗法和化疗。目前尚无单独针对PHNENs的治疗指南，本文就PHNENs的诊断和治疗进展作一综述。
    Primary hepatic neuroendocrine neoplasms (PHNENs) are a group of heterogenous tumors which originates from the liver and can secrete bioactive amines and polypeptide hormones. PHNENs are rare and represent only 0.3%~4.0% of all NENs. Most of PHNENs have no special clinical symptoms and imaging ﬁndings. It is difficult to be early diagnosed and distinguished from metastatic NENs. Surgery is the first choice of treatment and the only cure. Radiofrequency and hepatic artery em-bolization are used in the local treatment of unresectable PHNENs. The systematic therapies for PHNENs include biotherapy with somatostatin analogues, targeted therapies with mammalian ra-pamycin target protein and tyrosine kinase inhibitors, peptide receptor radionuclide therapy and chemotherapy. There is no definite guideline for treatment of PHNENs. This article reviewed the advances in diagnosis and treatment of PHNENs. 
  
 
</p></abstract><kwd-group><kwd>神经内分泌肿瘤，肝脏肿瘤，诊断，治疗, Neuroendocrine Neoplasms</kwd><kwd> Liver Tumor</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>原发性肝脏神经内分泌肿瘤的诊断和 治疗进展<sup> </sup></title><p>李梦霞<sup>1</sup>，李启勇<sup>2</sup>，肖慜<sup>2</sup>，郑树森<sup>1,2,3</sup></p><p><sup>1</sup>浙江大学医学院附属第一医院肝胆胰外科，浙江 杭州</p><p><sup>2</sup>树兰(杭州)医院肝胆胰外科，浙江 杭州</p><p><sup>3</sup>浙江大学医学院附属第一医院多器官联合移植重点实验室，浙江 杭州</p><p><img src="//html.hanspub.org/file/10-1570849x1_hanspub.png" /></p><p>收稿日期：2019年2月14日；录用日期：2019年2月28日；发布日期：2019年3月6日</p><disp-formula id="hanspub.29151-formula1"><graphic xlink:href="//html.hanspub.org/file/10-1570849x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>原发性肝脏神经内分泌肿瘤(Primary hepatic neuroendocrine neoplasms, PHNENs)特指原发于肝脏的一组能够分泌生物活性胺和多肽类激素的异质性肿瘤，临床罕见，仅占所有NENs的0.3%~4.0%。大部分PHNENs的临床症状和影像学表现缺乏特异性，早期诊断困难，与转移性NENs难以鉴别。手术是治疗的首选，也是唯一可以根治的方法。对于不可切除的PHNENs，肝脏局部治疗有射频和肝动脉栓塞，系统治疗方法主要包括生长抑素类似物的生物治疗，哺乳动物雷帕霉素靶蛋白和酪氨酸激酶抑制剂的靶向治疗，肽受体放射性核素疗法和化疗。目前尚无单独针对PHNENs的治疗指南，本文就PHNENs的诊断和治疗进展作一综述。</p><p>关键词 :神经内分泌肿瘤，肝脏肿瘤，诊断，治疗</p><disp-formula id="hanspub.29151-formula2"><graphic xlink:href="//html.hanspub.org/file/10-1570849x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1570849x7_hanspub.png" /> <img src="//html.hanspub.org/file/10-1570849x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>神经内分泌肿瘤(Neuroendocrine neoplasms, NENs)是一组能够分泌生物活性胺和多肽类激素的异质性肿瘤，可发生于全身各个存在神经内分泌细胞的器官和组织，最常见于胃、肠、胰腺等部位，约占所有NENs的65%~67% [<xref ref-type="bibr" rid="hanspub.29151-ref1">1</xref>] 。原发性肝脏神经内分泌肿瘤(Primary hepatic neuroendocrine neoplasms, PHNENs)特指原发于肝脏的NENs，仅占所有NENs的0.3%~4.0%，约占肝脏恶性肿瘤的0.28%~0.46% [<xref ref-type="bibr" rid="hanspub.29151-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref3">3</xref>] 。美国监测、流行病学和最终结果数据库(SEER)的研究数据表明，NENs的发病率在近几十年从1.09/10万上升为6.98/10万 [<xref ref-type="bibr" rid="hanspub.29151-ref4">4</xref>] ，但尚无确切数据统计PHNENs的发病率。肝脏NENs多为转移性(Metastatic HNENs, MHNENs)，PHNENs的发病率极低，临床误诊率高，其病因和发病机制至今尚不明确。目前还没单独针对PHNENs的治疗指南，我们对其的认识主要来于临床案例报道和回顾性分析，本文就PHNENs的诊断和治疗进展作一综述。</p></sec><sec id="s4"><title>2. 分类分级</title><p>本文对PHNENs的临床分类分级参考2010年WHO胃肠道NENs的分类标准 [<xref ref-type="bibr" rid="hanspub.29151-ref5">5</xref>] ，根据核分裂象数和Ki-67增殖指数，将其分为三种类型：1) 神经内分泌肿瘤(NET)：分化良好，恶性程度较低，包括G1级(核分裂象 &lt; 2个/Ki-67 &lt; 3%)和G2级(核分裂象为2~20个/Ki-67 3%~20%)；2) 神经内分泌癌(NEC)，低分化，恶性程度高，为G3级(核分裂象 &gt; 20个/Ki-67 &gt; 20%)；3) 混合腺内分泌癌(MANEC)：主要由腺癌和NEC两种成分组成且每种成分均占30%以上。</p></sec><sec id="s5"><title>3. 诊断</title><p>PHNENs的临床表现和影像学检查均缺乏特异性，诊断时需满足以下2个条件：1) 病理上符合NENs的诊断；2) 严格排除肝外原发灶。由于肿瘤的同源性，PHNENs和MHNENs在病理上难以鉴别，PHNENs的诊断是一个术前–术中–术后的长期过程，需全面检查和长期随访以排除任何潜在的肝外原发灶。</p><sec id="s5_1"><title>3.1. 临床表现</title><p>PHNENs的临床表现多不典型，根据症状是否与异常分泌的激素相关分为两类：功能性和非功能性。PHNENs多为非功能性，患者无明显症状，部分表现为腹痛、腹胀、腹部肿块等肿瘤占位性症状，若出现潮热、反复低血糖、腹泻、Zollinger-Ellison综合征等激素相关症状称为功能性PHNENs，可伴或不伴有肿瘤占位性表现 [<xref ref-type="bibr" rid="hanspub.29151-ref6">6</xref>] ，研究发现仅5%患者出现类癌综合征 [<xref ref-type="bibr" rid="hanspub.29151-ref7">7</xref>] 。患者多在常规体检或就诊其他疾病时偶然发现病灶，部分患者因肿瘤压迫胆管出现梗阻性黄疸或肿瘤牵扯肝脏包膜后出现腹痛就诊，还未有研究发现该病与病毒性肝炎、肝硬化等肝脏基础疾病相关。</p></sec><sec id="s5_2"><title>3.2. 实验室检查</title><p>PHNENs患者的AFP、CEA、CA19-9等常规肿瘤标志物多在正常范围内或轻度升高，诊治意义较小。对于功能性PHNENs，生物活性胺和多肽等代谢产物有利于疾病诊断，如5-羟色胺、胰岛素、胃泌素等。然而，大多数PHNENs为非功能性，缺乏特异性的生物标志物。</p><p>临床上较常检测的生物标志物包括嗜铬素A (CgA)、神经元特异性烯醇化酶(NSE)、5-羟吲哚乙酸(5-HIAA)等。CgA是一种亲水性糖蛋白，存在于所有神经内分泌细胞的分泌颗粒中，可在血清或血浆中测定，浓度水平与肿瘤体积、分化程度以及患者生存均有相关性 [<xref ref-type="bibr" rid="hanspub.29151-ref8">8</xref>] 。CgA的灵敏度和特异性分别为60%~90%和73%~95%，被认为是诊断NENs最有价值的肿瘤标记物 [<xref ref-type="bibr" rid="hanspub.29151-ref9">9</xref>] 。但其检测方法不一、缺乏标准化，在肾功能衰竭、心脏病、使用质子泵抑制剂等情况下也会升高，对NENs的诊断和随访存在局限性 [<xref ref-type="bibr" rid="hanspub.29151-ref10">10</xref>] 。Rocca A.等 [<xref ref-type="bibr" rid="hanspub.29151-ref11">11</xref>] 报道了一例PHNENs，术前血清CgA高达3972 U/L (正常范围2~18 U/L)，提示血清CgA有助于PHNENs的术前诊断。但PHNENs非常罕见，临床仅有少数病例行血清CgA检查，该结论缺乏大数据支持，建议在今后的诊治过程中完善血清Cg A检查，评估其在PHNENs中的应用价值。血清NSE是NEC诊断和随访的标记物之一，尤其是部分血清CgA阴性患者。5-HIAA是5-羟色胺的代谢产物，其在24小时尿中含量可用于诊断类癌综合征。一些新的生物标志物正在被研发，例如：多肽/生长因子、DNA/RNA标记物，循环肿瘤细胞等 [<xref ref-type="bibr" rid="hanspub.29151-ref12">12</xref>] 。灵敏度和特异度都高的特异性生物标记物是管理PHNENs的有效方法，也是当前的研究热点和难点，值得我们继续探索。HNENs的临床表现多不典型，根据症状是否与异常分泌的激素相关分为两类：功能性和非功能性。</p></sec><sec id="s5_3"><title>3.3. 影像学检查</title><sec id="s5_3_1"><title>3.3.1. 常规影像学检查</title><p>研究发现，PHNENs好发于肝脏右叶，病灶一般较大(直径 &gt; 5 cm)，呈圆形或不规则状，多为单发，多发时可表现为1个较大的病灶周围有多个子灶。常规的影像学检查包括B超、CT、MRI等：1) B超显示肿瘤多为混合性高回声，少数呈等回声或低回声，边界清晰。在超声造影中，80%以上的病例表现为动脉期迅速强化，门静脉和延迟期明显减退，呈“快进快出”模式 [<xref ref-type="bibr" rid="hanspub.29151-ref13">13</xref>] ；2) CT平扫表现为低密度灶，肿瘤较大时可发生出血、坏死或囊性等改变，病灶密度不均匀，其内可见更低密度区 [<xref ref-type="bibr" rid="hanspub.29151-ref14">14</xref>] ；3) MRI平扫表现为T1低信号，T2稍高信号，DWI明显高信号，更易发现隐匿性病灶 [<xref ref-type="bibr" rid="hanspub.29151-ref15">15</xref>] ；4) 在增强CT/MRI中，病灶多由边缘至中心逐渐强化，随后呈持续性强化或者减退，坏死或囊性改变部分不增强 [<xref ref-type="bibr" rid="hanspub.29151-ref15">15</xref>] 。PHNENs的常规影像学表现无特异性，与其他肝脏肿瘤难以鉴别，但有助于肿瘤定位、评估与周围组织的关系，指导进一步治疗及长期监测。结合胸部CT、胃镜、肠镜等检查可以排除肺、胃肠道等肝外来源，最终确诊仍需结合病理诊断 [<xref ref-type="bibr" rid="hanspub.29151-ref16">16</xref>] 。</p></sec><sec id="s5_3_2"><title>3.3.2. 功能性成像检查</title><p>近年来，功能性成像技术迅速发展并广泛应用于临床。NENs细胞表面高表达生长抑素受体(SSTR，主要为SSTR-2和SSTR-5)，生长抑素或生长抑素类似物(SSA)可与其特异性结合。生长抑素受体显像(SRS)利用放射性核素标记SSA，与肿瘤细胞表面的SSTR特异性结合从而使肿瘤显像，灵敏度高达90%，特异性为83%，目前被认为是NENs功能成像诊断的金标准 [<xref ref-type="bibr" rid="hanspub.29151-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref17">17</xref>] ，也是生物疗法的治疗基础。最常用的显影剂是奥曲肽(<sup>111</sup>In-DTPA-奥曲肽、<sup>99</sup>mTc-奥曲肽)。SSA不适用于SSTR阴性患者，对于1 cm以下的病灶显示不佳 [<xref ref-type="bibr" rid="hanspub.29151-ref18">18</xref>] 。PHNENs多为非功能性，SSA的成像阳性率尚不清楚，但SSA有助于发现肝外原发灶并鉴别PHNENs和MHNENs。</p><p>正电子发射型计算机断层显像(PET-CT)，利用发射正电子的放射性核素标记相关代谢物质，结合高分辨率CT成像，能够反映肿瘤的代谢，检出3~6 mm的病灶，较SRS更灵敏，特异性更高 [<xref ref-type="bibr" rid="hanspub.29151-ref18">18</xref>] 。正电子显像剂主要为<sup>68</sup>Ga标记的奥曲肽(<sup>68</sup>Ga-DOTATATE, <sup>68</sup>Ga-DOTATOC，<sup>68</sup>Ga-DOTANOC)和<sup>18</sup>F标记的氟代脱氧葡萄糖(<sup>18</sup>F-FDG)。Deppen S. A.等 [<xref ref-type="bibr" rid="hanspub.29151-ref19">19</xref>] 研究对比了<sup>68</sup>Ga PET-CT与SRS在NENs诊断、分期和治疗中的安全性和有效性，发现<sup>68</sup>Ga PET-CT诊断更精准，尤其是对于分化良好、高表达SSTR的NENs的诊断。其检查时间短，药物无明显毒性，辐射剂量更低，在经济、设备等条件允许的情况下，<sup>68</sup>Ga PET-CT有望取代SRS成为PHNENs功能成像检查的首选 [<xref ref-type="bibr" rid="hanspub.29151-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref21">21</xref>] 。<sup>18</sup>F-FDGPET/CT信号的强度取决于摄取葡萄糖的组织亲和力，对于高分化、增殖不活跃的NET敏感性低，但对于侵袭性强、增殖活跃、肿瘤负荷大的NEC有一定诊断价值 [<xref ref-type="bibr" rid="hanspub.29151-ref22">22</xref>] 。Panagiotidis E.等 [<xref ref-type="bibr" rid="hanspub.29151-ref23">23</xref>] 研究发现，在低分化NENs中，<sup>18</sup>F-FDG PET/CT与<sup>68</sup>Ga-DOTATE联合使用能够加强诊断作用。</p></sec></sec><sec id="s5_4"><title>3.4. 病理学检查</title><p>病理学检查是NENs诊断的金标准，主要通过穿刺活检或手术获得病理组织 [<xref ref-type="bibr" rid="hanspub.29151-ref24">24</xref>] 。核分裂象数和Ki-67增殖指数是肿瘤分型分级的基础 [<xref ref-type="bibr" rid="hanspub.29151-ref5">5</xref>] 。CgA、NSE、突触素(Syn)和CD56是NENs的特异性免疫组化检测指标。与其他NENs相比，PHNENs并没有特别的组织学特性。多项回顾性研究分析发现，病理结果可以评估PHNENs预后。Chen等 [<xref ref-type="bibr" rid="hanspub.29151-ref25">25</xref>] 报告了28例PHNENs，发现高Ki-67是预后的一个独立危险因素。Shi等 [<xref ref-type="bibr" rid="hanspub.29151-ref26">26</xref>] 回顾分析了22例手术治疗的PHNENs，发现病理高分化(G1/G2)是PHNENs预后的有利因素。</p><p>以往认为，仅从病理上无法区分PHNENs和MHNENs。Maxwell je等 [<xref ref-type="bibr" rid="hanspub.29151-ref27">27</xref>] 和Yang Z.等 [<xref ref-type="bibr" rid="hanspub.29151-ref28">28</xref>] 近期研究发现病理免疫组化或可提示肿瘤原发灶，有助于疾病管理，降低误诊漏诊率。Alexandraki K.等 [<xref ref-type="bibr" rid="hanspub.29151-ref29">29</xref>] 归纳了目前可用于推测MHNENs原发灶的组织病理学标记物，例如：TTF 1是肺发育过程中的重要转录因子，可作为肺来源的特殊标志；CDX 2在肠道发育中起关键作用，提示肠道来源；PAX 6/8和ISL 1提示胰十二指肠或直肠来源，若同时存在NESP 55阳性则更倾向胰腺来源。需要强调的是，以上结果主要来自于NET的研究，也仅适用该类肿瘤。</p></sec></sec><sec id="s6"><title>4. 治疗</title><p>迄今为止，PHNENs尚无明确的治疗标准，根据肿瘤的部位、大小、病理特点及患者的具体情况选择治疗方案，主要以手术为主，结合肝脏局部治疗、生物疗法、放射性核素疗法、分子靶向治疗、化疗等方法综合治疗。</p><sec id="s6_1"><title>4.1. 手术治疗</title><sec id="s6_1_1"><title>4.1.1. 手术切除</title><p>手术是治疗PHNENs的首选。Lwao M.等 [<xref ref-type="bibr" rid="hanspub.29151-ref30">30</xref>] 回顾分析了53例PHNENs，肿瘤可切除率高达85%，但也有文献 [<xref ref-type="bibr" rid="hanspub.29151-ref3">3</xref>] 表示PHNENs初诊时已有50%发生肝内或者远处转移。Meng X. F.等 [<xref ref-type="bibr" rid="hanspub.29151-ref17">17</xref>] 报道了一例病史长达26年的PHNENs，术后8年无复发。Nishimori H.等 [<xref ref-type="bibr" rid="hanspub.29151-ref31">31</xref>] 报道了一例术后13年复发的PHNENs。据统计 [<xref ref-type="bibr" rid="hanspub.29151-ref32">32</xref>] ，PHNENs术后5年存活率为74%~78%，复发率为18%~26%，手术可明显改善预后 [<xref ref-type="bibr" rid="hanspub.29151-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref33">33</xref>] ，但术后复发率较高，长期随访非常重要。Qu C.等 [<xref ref-type="bibr" rid="hanspub.29151-ref34">34</xref>] 新近报道了一例大小为13 &#215; 7 &#215; 6 cm的PHNENs，成功行肝脏离断和门静脉结扎的二步肝切除术，达到肿瘤根治效果。对于肿瘤过大或病灶较多，无法一次切除的PHNENs，姑息性切除或者二次手术或可改善预后，但仍需大宗数据研究。</p></sec><sec id="s6_1_2"><title>4.1.2. 肝移植</title><p>米兰标准和欧洲指南等提出MHNENs肝移植需满足以下条件：年龄 &lt; 55岁、原发肿瘤已切除且观察6个月以上未发现肝外转移、肿瘤分化良好(G1/G2，Ki 67 &lt; 10%)、&lt;50%肝脏受累 [<xref ref-type="bibr" rid="hanspub.29151-ref35">35</xref>] 。Sposito，C.等 [<xref ref-type="bibr" rid="hanspub.29151-ref35">35</xref>] 回顾了多项研究，参考上述标准严格选取患者，移植术后5年累计生存率(69%~97%)明显高于非手术治疗的患者(34%~51%)。对于肿瘤过大、病灶多发、位置特殊等原因导致无法手术且其他治疗欠佳，但无肝外转移的PHNENs，肝移植是一种理想的治疗方法。必须指出的是，PHNENs病例较少，肝移植经验有限，暂无相应的指南和标准，且存在供体短缺和高复发率等问题 [<xref ref-type="bibr" rid="hanspub.29151-ref36">36</xref>] 。总之，肝移植治疗PHNENs仍有争议，有待进一步临床研究 [<xref ref-type="bibr" rid="hanspub.29151-ref37">37</xref>] 。</p></sec></sec><sec id="s6_2"><title>4.2. 肝脏局部治疗</title><sec id="s6_2_1"><title>4.2.1. 消融技术</title><p>主要包括射频消融(RFA)、微波消融、冷冻消融等。RFA是最常用的热消融，可单独或联合手术治疗PHNENs，一般用于治疗数量 &lt; 5个且直径 &lt; 5 cm的病灶 [<xref ref-type="bibr" rid="hanspub.29151-ref38">38</xref>] 。术后出血、消融不完全、肝功能受损是常见的并发症，术后肿瘤复发率高，不适用于多发转移和肝门部或大血管周围的病灶。近年来，不可逆电穿孔消融技术逐渐成熟，作为精准的非热消融，不损伤血管、胆管、神经等结构，且无“热沉效应”，有望成为PHNENs新的治疗方法 [<xref ref-type="bibr" rid="hanspub.29151-ref39">39</xref>] 。</p></sec><sec id="s6_2_2"><title>4.2.2. 肝动脉栓塞技术</title><p>局部血管栓塞联合药物治疗可以有效控制症状、延缓肿瘤生长甚至达到减瘤效果。肝动脉化疗栓塞术(TACE)是首选的局部介入治疗 [<xref ref-type="bibr" rid="hanspub.29151-ref40">40</xref>] ，高化疗药物浓度(主要为阿霉素、链脲霉素等)和缺血均能增强肿瘤细胞对药物的反应。临床研究发现40%~100%的HNENs在TACE治疗后症状明显缓解，常见的副作用是发热、腹痛、恶心和肝酶升高，通常是一过性的，部分患者会出现肝脓肿、肝功能衰竭等严重并发症 [<xref ref-type="bibr" rid="hanspub.29151-ref38">38</xref>] 。放射性栓塞(RE)将90Y放射微球代替化疗药物，可以同时达到选择性肿瘤内放射的治疗目的。Braat，Ajat [<xref ref-type="bibr" rid="hanspub.29151-ref41">41</xref>] 等研究244例MHNENs，RE术后肿瘤有效控制率为91%，症状缓解率为79%，中位生存时间为31个月，最常见不良反应为淋巴细胞减少，与RE相关的并发症发生率 &lt; 4%，证明RE是一个安全有效的局部治疗方式。在TACE治疗失败后，RE治疗仍有效果 [<xref ref-type="bibr" rid="hanspub.29151-ref42">42</xref>] ，提示RE或可替代TAE/TACE成为栓塞治疗的首选 [<xref ref-type="bibr" rid="hanspub.29151-ref43">43</xref>] 。</p></sec></sec><sec id="s6_3"><title>4.3. 生物疗法</title><sec id="s6_3_1"><title>4.3.1 . 生长抑素类似物(SSA)</title><p>SSA (包括奥曲肽、兰瑞肽等)通过与SSTR结合抑制激素分泌，用于控制激素相关临床症状，主要治疗功能性NENs，对分化良好、低增殖、肿瘤负荷较小的NENs疗效更佳 [<xref ref-type="bibr" rid="hanspub.29151-ref44">44</xref>] 。研究发现其细胞毒性和细胞抑制作用可以抗肿瘤增殖，治疗功能性和非功能性NENs的效果相似 [<xref ref-type="bibr" rid="hanspub.29151-ref45">45</xref>] 。患者对SSA耐受性较好，少数患者出现注射部位疼痛和胃肠道副作用。SSA主要控制肿瘤增长，但治疗后肿瘤缩小少有报道，临床需联合其他方法综合治疗NENs。PHNENs多为非功能性，SSA对其具体的治疗效果尚不清楚，部分患者存在药物过敏，临床使用需谨慎 [<xref ref-type="bibr" rid="hanspub.29151-ref46">46</xref>] 。</p></sec><sec id="s6_3_2"><title>4.3.2 . α干扰素</title><p>与SSA类似，α干扰素具有抗细胞增殖分化的作用 [<xref ref-type="bibr" rid="hanspub.29151-ref47">47</xref>] ，但白细胞减少、肝肾毒性、骨髓抑制等不良反应较多，不建议作为治疗首选，主要用于治疗SSA抵抗或者不能耐受的难治性功能性NENs [<xref ref-type="bibr" rid="hanspub.29151-ref48">48</xref>] 。</p></sec></sec><sec id="s6_4"><title>4.4. 肽受体放射性核素疗法</title><p>肽受体放射性核素治疗(PRRT)利用放射性核素(如<sup>90</sup>Y或<sup>177</sup>Lu)标记SSA，有效结合了放射性核素对肿瘤的内放疗作用和SSA的定位显像及抗细胞增殖作用，疾病控制率为68%~94%，是治疗高表达SSTR的晚期NENs的有效方法 [<xref ref-type="bibr" rid="hanspub.29151-ref49">49</xref>] 。在一项随机Ⅲ期临床试验中，Strosberg J等 [<xref ref-type="bibr" rid="hanspub.29151-ref50">50</xref>] 评估了<sup>177</sup>Lu-Dotatate治疗分化良好的晚期NENs的反应性和有效性，<sup>177</sup>Lu-Dotatate组的治疗反应率和疾病无进展率明显高于奥曲肽组(18% vs. 3%；65% vs. 11%)，研究结果表明，PRRT治疗效果明显优于奥曲肽。Carlsen E. A. [<xref ref-type="bibr" rid="hanspub.29151-ref51">51</xref>] 等回顾分析了PRRT治疗低分化(G3级)NENs的有效性和安全性，共纳入12个中心，114名患者。结果显示：疾病控制率为69%，中位无进展生存期(PFS)为14个月，总体生存期为29个月，3~4级的血液学毒性或肾毒性发生率为17%。目前PRRT治疗HNENs的研究多集中在MHNENs，对于PHNENs有无明确疗效仍需大样本研究。</p></sec><sec id="s6_5"><title>4.5. 分子靶向治疗</title><sec id="s6_5_1"><title>4.5.1. 哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂</title><p>mTOR是一种丝氨酸/苏氨酸蛋白激酶，主要参与调节细胞生长、增殖和新陈代谢。研究发现，mTOR在多种肿瘤细胞中均有过度激活，mTOR抑制剂通过阻断PI3K-AKT-mTOR信号通路激活达到抑制肿瘤作用 [<xref ref-type="bibr" rid="hanspub.29151-ref52">52</xref>] 。依维莫司是一种口服mTOR抑制剂，已被批准用于治疗分化良好的胃肠道非功能性NENs [<xref ref-type="bibr" rid="hanspub.29151-ref53">53</xref>] 。Singh S.等 [<xref ref-type="bibr" rid="hanspub.29151-ref54">54</xref>] 纳入302名NENs患者，按照2:1随机接受依维莫司或安慰剂治疗, 直至疾病进展。结果显示：在胃肠道来源组，依维莫司治疗组的中位PFS为13.1个月，安慰剂组为5.4个月。在原发灶不明组，依维莫司治疗组的中位PFS为13.6个月，安慰剂组为7.5个月。两组接受依维莫司治疗的患者疾病进展率降低40%~46%，证明其有效延长了患者PFS及提高无进展生存率。依维莫司治疗有关的常见副作用为口腔炎、感染、腹泻、外周水肿和疲劳等。由于PHNENs病例较少，尚无研究证明mTOR抑制剂对治疗PHNENs有效。</p></sec><sec id="s6_5_2"><title>4.5.2. 多靶点酪氨酸激酶抑制剂(MTKI)</title><p>舒尼替尼是一种被批准用于晚期胰腺NENs的MTKI，主要通过抑制血管内皮生长因子、胰岛素样生长因子、成纤维细胞生长因子等多种酪氨酸激酶，减少新生血管生成，抑制肿瘤细胞生长增殖和转移播散 [<xref ref-type="bibr" rid="hanspub.29151-ref55">55</xref>] [<xref ref-type="bibr" rid="hanspub.29151-ref56">56</xref>] 。大量新的或已批准用于其他肿瘤的MKTI正被研究应用于NENs，部分已进入临床试验阶段。Grillo F.等 [<xref ref-type="bibr" rid="hanspub.29151-ref55">55</xref>] 统计分析了阿西替尼、卡博替尼、帕唑帕尼等七种MKTI治疗NENs的有效应和安全性，共11项临床试验，招募人数达1667名。部分研究结果显示：帕唑帕尼治疗晚期胰腺NENs是有效的且患者耐受性良好；阿西替尼对于晚期非胰腺NENs具有抗肿瘤作用，但患者易出现严重高血压；索拉非尼与贝伐单抗联用可以有效治疗晚期NENs，但粘膜损伤、肝功能异常、药物性高血压等副作用发生率高。</p></sec></sec><sec id="s6_6"><title>4.6. 化学治疗</title><p>对于增殖活跃、生长迅速、低分化、恶性程度高的NEC，全身系统化疗是一种有效的方法，铂类药物(顺铂/卡铂)联合依托泊苷是首选的化疗方案 [<xref ref-type="bibr" rid="hanspub.29151-ref57">57</xref>] 。对于高分化、低增殖的NET，化疗效果有限，一般不做一线治疗。研究发现，对于高分化的进展期NENs或其他治疗失败且SSTR表达阴性的患者，尤其是增殖活跃的病灶(Ki-67 &gt; 55%)，替莫唑胺单药或者联合卡培他滨是一种有效的化疗方案 [<xref ref-type="bibr" rid="hanspub.29151-ref58">58</xref>] 。化疗常见副作用为恶心呕吐等胃肠道反应、白细胞减少、黏膜炎、手足综合征等。替莫唑胺经肾脏代谢，对于有严重肝肾功能损害的患者，应谨慎使用。目前对于PHNENs的化疗缺乏临床经验，多参照上述化疗方案，考虑到药物细胞毒性累积作用可能会增加不良事件的发生率，故系统化疗多在疾病进展和其他治疗无效后考虑 [<xref ref-type="bibr" rid="hanspub.29151-ref59">59</xref>] 。</p></sec></sec><sec id="s7"><title>5. 结语</title><p>综上所述，PHNENs较为罕见，临床诊断困难，在病理诊断的基础上，需联合各项检查排除MHNENs后确诊。手术切除仍是目前最有效的治疗手段，对于晚期PHNENs，可综合选择肝脏局部治疗、SSA的生物疗法、mTOR抑制剂和MTKI的分子靶向治疗、PRRT以及化疗等方法，肝移植需严格把握适应症。充分评估目前PHNENs诊治方法的有效性，从分子层面探索和发现特异性生物标志物和新的治疗靶点，对PHNENs的诊断和治疗至关重要，值得进一步深入研究。</p></sec><sec id="s8"><title>文章引用</title><p>李梦霞,李启勇,肖 慜,郑树森. 原发性肝脏神经内分泌肿瘤的诊断和治疗进展Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms[J]. 临床医学进展, 2019, 09(03): 225-234. https://doi.org/10.12677/ACM.2019.93035</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29151-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Burad, D.K., Kodiatte, T.A., Rajeeb, S.M., et al. (2016) Neuroendocrine Neoplasms of Liver—A 5-Year Retrospective Clinicopathological Study Applying World Health Organization 2010 Classification. World Journal of Gastroenterology, 22, 8956-8966. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i40.8956</mixed-citation></ref><ref id="hanspub.29151-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Parkash, O., Ayub, A., Naeem, B., et al. (2016) Primary Hepatic Carcinoid Tumor with Poor Outcome. Journal of the College of Physicians and Surgeons—Pakistan, 26, 227-229.</mixed-citation></ref><ref id="hanspub.29151-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">李晓琼, 张华, 李健丁. 肝脏原发性神经内分泌肿瘤的研究现状[J]. 世界华人消化杂志, 2013, 21(11): 984-989.</mixed-citation></ref><ref id="hanspub.29151-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.  
&lt;br&gt;https://doi.org/10.1001/jamaoncol.2017.0589</mixed-citation></ref><ref id="hanspub.29151-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Flejou, J.F. (2011) WHO Classification of Digestive Tumors: The Fourth Edition. Annales de Pathologie, 31, S27-S31.  
&lt;br&gt;https://doi.org/10.1016/j.annpat.2011.08.001</mixed-citation></ref><ref id="hanspub.29151-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kulke, M.H., Shah, M.H., Benson 3rd, A.B., et al. (2015) Neuroendocrine Tumors, Version 1. Journal of the National Comprehensive Cancer Network, 13, 78-108. &lt;br&gt;https://doi.org/10.6004/jnccn.2015.0011</mixed-citation></ref><ref id="hanspub.29151-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Park, C.H., Chung, J.W., Jang, S.J., et al. (2012) Clinical Features and Outcomes of Primary Hepatic Neuroendocrine Carcinomas. Journal of Gastroenterology and Hepatology, 27, 1306-1311.  
&lt;br&gt;https://doi.org/10.1111/j.1440-1746.2012.07117.x</mixed-citation></ref><ref id="hanspub.29151-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Marotta, V., Zatelli, M.C., Sciammarella, C., et al. (2018) Chromogranin A as Circulating Marker for Diagnosis and Management of Neuroendocrine Neoplasms: More Flaws Than Fame. Endocrine-Related Cancer, 25, R11-R29.  
&lt;br&gt;https://doi.org/10.1530/ERC-17-0269</mixed-citation></ref><ref id="hanspub.29151-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hofland, J., Zandee, W.T. and De Herder, W.W. (2018) Role of Bi-omarker Tests for Diagnosis of Neuroendocrine Tumours. Nature Reviews Endocrinology, 14, 656-669. &lt;br&gt;https://doi.org/10.1038/s41574-018-0082-5</mixed-citation></ref><ref id="hanspub.29151-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Deluzio, M.R., Barbieri, A.L., Israel, G., et al. (2017) Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Annals of Hepatology, 16, 621-629. &lt;br&gt;https://doi.org/10.5604/01.3001.0010.0313</mixed-citation></ref><ref id="hanspub.29151-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rocca, A., Calise, F., Marino, G., et al. (2014) Primary Giant Hepatic Neuroendocrine Carcinoma: A Case Report. International Journal of Surgery, 12, 218-221. &lt;br&gt;https://doi.org/10.1016/j.ijsu.2014.05.056</mixed-citation></ref><ref id="hanspub.29151-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Herrera Martinez, A.D., Hofland, L., Galvez Moreno, M.A., et al. (2019) Neuroendocrine Neoplasms: Current and Potential Diagnostic, Predictive and Prognostic Markers. Endo-crine-Related Cancer, 26, R157-R179.  
&lt;br&gt;https://doi.org/10.1530/ERC-18-0354</mixed-citation></ref><ref id="hanspub.29151-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Zhuang, B.W., Wang, Z., et al. (2016) Case Report of Con-trast-Enhanced Ultrasound Features of Primary Hepatic Neuroendocrine Tumor: A CARE-Compliant Article. Medicine, 95, e3450.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000003450</mixed-citation></ref><ref id="hanspub.29151-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.X., Liu, K., Lin, G.W., et al. (2015) Primary He-patic Neuroendocrine Tumors: Comparing CT and MRI Features with Pathology. Cancer Imaging, 15, 13. &lt;br&gt;https://doi.org/10.1186/s40644-015-0046-0</mixed-citation></ref><ref id="hanspub.29151-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yang, K., Cheng, Y.S., Yang, J.J., et al. (2017) Primary Hepatic Neuroendocrine Tumors: Multi-Modal Imaging Features with Pathological Correlations. Cancer Imaging, 17, 20. &lt;br&gt;https://doi.org/10.1186/s40644-017-0120-x</mixed-citation></ref><ref id="hanspub.29151-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">郑琴芳, 何志钧, 农兵. 原发性肝脏神经内分泌肿瘤诊断的研究进展芳[J]. 胃肠病学, 2018, 23(8): 506-508.</mixed-citation></ref><ref id="hanspub.29151-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Meng, X.F., Pan, Y.W., Wang, Z.B., et al. (2018) Primary Hepatic Neuroendocrine Tumor Case with a Preoperative Course of 26 Years: A Case Report and Literature Review. World Journal of Gastroenterology, 24, 2640-2646.  
&lt;br&gt;https://doi.org/10.3748/wjg.v24.i24.2640</mixed-citation></ref><ref id="hanspub.29151-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yu, R. and Wachsman, A. (2017) Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls. Endocrinology &amp; Metabolism Clinics of North America, 46, 795-814. &lt;br&gt;https://doi.org/10.1016/j.ecl.2017.04.008</mixed-citation></ref><ref id="hanspub.29151-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Deppen, S.A., Liu, E., Blume, J.D., et al. (2016) Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Journal of Nuclear Medicine, 57, 708-714.  
&lt;br&gt;https://doi.org/10.2967/jnumed.115.163865</mixed-citation></ref><ref id="hanspub.29151-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Barrio, M., Czernin, J., Fanti, S., et al. (2017) The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 58, 756-761. &lt;br&gt;https://doi.org/10.2967/jnumed.116.185587</mixed-citation></ref><ref id="hanspub.29151-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. &lt;br&gt;https://doi.org/10.3322/caac.21493</mixed-citation></ref><ref id="hanspub.29151-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ma, G., Li, J., Xu, B., et al. (2018) 18F-FDG PET/CT in Primary Hepatic Neuroendocrine Tumors. Clinical Nuclear Medicine, 43, 192-194. &lt;br&gt;https://doi.org/10.1097/RLU.0000000000001938</mixed-citation></ref><ref id="hanspub.29151-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Panagiotidis, E., Alshammari, A., Michopoulou, S., et al. (2017) Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 58, 91-96. &lt;br&gt;https://doi.org/10.2967/jnumed.116.178095</mixed-citation></ref><ref id="hanspub.29151-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Song, J.E., Kim, B.S. and Lee, C.H. (2016) Primary Hepatic Neuroendocrine Tumor: A Case Report and Literature Review. World Journal of Clinical Cases, 4, 243-247. &lt;br&gt;https://doi.org/10.12998/wjcc.v4.i8.243</mixed-citation></ref><ref id="hanspub.29151-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Chen, R.W., Qiu, M.J., Chen, Y., et al. (2018) Analysis of the Clinicopathological Features and Prognostic Factors of Primary Hepatic Neuroendocrine Tumors. Oncology Letters, 15, 8604-8610. &lt;br&gt;https://doi.org/10.3892/ol.2018.8413</mixed-citation></ref><ref id="hanspub.29151-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Shi, C., Zhao, Q., Dai, B., et al. (2018) Primary Hepatic Neuroendocrine Neoplasm: Long-Time Surgical Outcome and Prognosis. Medicine, 97, e11764. &lt;br&gt;https://doi.org/10.1097/MD.0000000000011764</mixed-citation></ref><ref id="hanspub.29151-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Maxwell, J.E., Sherman, S.K., Stashek, K.M., et al. (2014) A Practical Method to Determine the Site of Unknown Primary in Metastatic Neuroendocrine Tumors. Surgery, 156, 1359-1365. &lt;br&gt;https://doi.org/10.1016/j.surg.2014.08.008</mixed-citation></ref><ref id="hanspub.29151-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Z., Klimstra, D.S., Hruban, R.H., et al. (2017) Immunohistochemical Characterization of the Origins of Metastatic Well-Differentiated Neuroendocrine Tumors to the Liver. The American Journal of Surgical Pathology, 41, 915-922. &lt;br&gt;https://doi.org/10.1097/PAS.0000000000000876</mixed-citation></ref><ref id="hanspub.29151-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Alexandraki, K., Angelousi, A., Boutzios, G., et al. (2017) Management of Neuroendocrine Tumors of Unknown Primary. Reviews in Endocrine &amp; Metabolic Disorders, 18, 423-431. &lt;br&gt;https://doi.org/10.1007/s11154-017-9437-9</mixed-citation></ref><ref id="hanspub.29151-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Iwao, M., Nakamuta, M., Enjoji, M., et al. (2001) Pri-mary Hepatic Carcinoid Tumor: Case Report and Review of 53 Cases. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 7, 746-750.</mixed-citation></ref><ref id="hanspub.29151-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nishimori, H., Tsuji, K., Miyamoto, N., et al. (2005) Recurrence of Primary Hepatic Carcinoid Tumor in the Remnant Liver 13 yr after Resection. International Journal of Gastrointestinal Cancer, 35, 147-151.  
&lt;br&gt;https://doi.org/10.1385/IJGC:35:2:147</mixed-citation></ref><ref id="hanspub.29151-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Knox, C.D., Anderson, C.D., Lamps, L.W., et al. (2003) Long-Term Survival after Resection for Primary Hepatic Carcinoid Tumor. Annals of Surgical Oncology, 10, 1171-1175. &lt;br&gt;https://doi.org/10.1245/ASO.2003.04.533</mixed-citation></ref><ref id="hanspub.29151-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Tamburrino, D., Spoletini, G., Partelli, S., et al. (2016) Surgical Management of Neuroendocrine Tumors. Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism, 30, 93-102. &lt;br&gt;https://doi.org/10.1016/j.beem.2015.10.003</mixed-citation></ref><ref id="hanspub.29151-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Qu, C., Qu, L.L., Zhu, C.Z., et al. (2018) Treatment of Primary Hepatic Neuroendocrine Tumors with Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): A Case Report and Literature Review. Medicine, 97, e12408. &lt;br&gt;https://doi.org/10.1097/MD.0000000000012408</mixed-citation></ref><ref id="hanspub.29151-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Sposito, C., Droz dit Busset, M., Citterio, D., et al. (2017) The Place of Liver Transplantation in the Treatment of Hepatic Metastases from Neuroendocrine Tumors: Pros and Cons. Reviews in Endocrine &amp; Metabolic Disorders, 18, 473-483. &lt;br&gt;https://doi.org/10.1007/s11154-017-9439-7</mixed-citation></ref><ref id="hanspub.29151-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">吕品, 孙世波, 陈晓宁. 原发性肝脏神经内分泌肿瘤的诊治进展[J]. 肝胆胰外科杂志, 2017, 29(6): 511-514.</mixed-citation></ref><ref id="hanspub.29151-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Moris, D., Tsilimigras, D.I., Ntanasis-Stathopoulos, I., et al. (2017) Liver Transplantation in Patients with Liver Me 
tastases from Neuroendocrine Tumors: A Systematic Review. Surgery, 162, 525-536.  
&lt;br&gt;https://doi.org/10.1016/j.surg.2017.05.006</mixed-citation></ref><ref id="hanspub.29151-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Uri, I., Avniel-Polak, S., Gross, D.J., et al. (2017) Update in the Therapy of Advanced Neuroendocrine Tumors. Current Treatment Options in Oncology, 18, 72.</mixed-citation></ref><ref id="hanspub.29151-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Niessen, C., Thumann, S., Beyer, L., et al. (2017) Percutaneous Irreversible Electroporation: Long-Term Survival  
Analysis of 71 Patients with Inoperable Malignant Hepatic Tumors. Scientific Reports, 7, Article No. 43687.  
&lt;br&gt;https://doi.org/10.1038/srep43687</mixed-citation></ref><ref id="hanspub.29151-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Do Minh, D., Chapiro, J., Gorodetski, B, et al. (2017) Intra-Arterial Therapy of Neuroendocrine Tumour Liver Metastases: Comparing Conventional TACE, Drug-Eluting Be Ads TACE and yttrium-90 Radioembolisation as Treatment Options Using a Propensity Score Analysis Model. European Radiology, 27, 4995-5005.  
&lt;br&gt;https://doi.org/10.1007/s00330-017-4856-2</mixed-citation></ref><ref id="hanspub.29151-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Braat, A., Kappadath, S.C., Ahmadzadehfar, H., et al. (2019) Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovascular and Interventional Radiology, 42, 413-425. &lt;br&gt;https://doi.org/10.1007/s00270-018-2148-0</mixed-citation></ref><ref id="hanspub.29151-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Jia, Z. Wang, W. (2018) Yttrium-90 Radioembolization for Un-resectable Metastatic Neuroendocrine Liver Tumor: A Systematic Review. European Journal of Radiology, 100, 23-29. &lt;br&gt;https://doi.org/10.1016/j.ejrad.2018.01.012</mixed-citation></ref><ref id="hanspub.29151-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Kennedy, A., Bester, L., Salem, R, et al. (2015) Role of Hepatic IntRa-ARTERIAL Therapies in Metastatic Neuroendocrine Tumours (NET): Guidelines from the NET-LIVER-Metastases Consensus Conference. Hpb: The Official Journal of the International Hepato Pancreato Biliary Association, 17, 29-37. &lt;br&gt;https://doi.org/10.1111/hpb.12326</mixed-citation></ref><ref id="hanspub.29151-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Merola, E.F. and Delle, 2017,A..F. () An-tiproliferative Effect of Somatostatin Tumors: A Systematic Review and Meta-Analysis. Oncotarget, 8, 46624-46634. &lt;br&gt;https://doi.org/10.18632/oncotarget.16686</mixed-citation></ref><ref id="hanspub.29151-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Rinke, A., Muller, H.H., Schade-Brittinger, C., et al. (2009) Pla-cebo-Controlled, Double-blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. Journal of Clinical Oncology, 27, 4656-4663.  
&lt;br&gt;https://doi.org/10.1200/JCO.2009.22.8510</mixed-citation></ref><ref id="hanspub.29151-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Z.M., Wang, J., Ugwuowo, U.C., et al. (2018) Primary Hepatic Neuroendocrine Carcinoma: Report of Two Cases and Literature Review. BMC Clinical Pathology, 18, 3.</mixed-citation></ref><ref id="hanspub.29151-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Yao, J.C., Guthrie, K.A., Moran, C., et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide plus Interferon Alfa-2b versus Depot Octreotide plus Bevacizumab in Patients with Advanced Carcinoid Tumors: SWOG S0518. Journal of Clinical Oncology, 35, 1695-1703. &lt;br&gt;https://doi.org/10.1200/JCO.2016.70.4072</mixed-citation></ref><ref id="hanspub.29151-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Shah, M.H., Goldner, W.S., Halfdanarson, T.R., et al.( 2018) NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal of the National Compre-hensive Cancer Network, 16, 693-702.  
&lt;br&gt;https://doi.org/10.1038/srep43687 
&lt;br&gt;https://doi.org/10.6004/jnccn.2018.0056</mixed-citation></ref><ref id="hanspub.29151-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Bodei, L., kwekkeboom, D.J., Kidd, M., et al. (2016) Radiolabeled Somatostatin Analogue Therapy of Gastroenteropancreatic CANCER. Seminars in Nuclear medicine, 46, 225-238. &lt;br&gt;https://doi.org/10.1053/j.semnuclmed.2015.12.003</mixed-citation></ref><ref id="hanspub.29151-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Strosberg, J., El-Haddad, G., Wolin, E., et al. (2017) Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal of Medicine, 376, 125-135. &lt;br&gt;https://doi.org/10.1056/NEJMoa1607427</mixed-citation></ref><ref id="hanspub.29151-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Carlsen, E.A., Fazio, N., Granberg, D, et al. (2019) Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic NEN G3: A Multicenter Cohort Study. Endocrine-Related Cancer, 26, 227-239. &lt;br&gt;https://doi.org/10.1530/ERC-18-0424</mixed-citation></ref><ref id="hanspub.29151-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Lamberti, G., Brighi, N., Maggio, I., et al. (2018) The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? International Journal of Molecular Sciences, 19.</mixed-citation></ref><ref id="hanspub.29151-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Chan, D.L., Segelov, E. and Singh, S. (2018) Everolimus in the Management of Metastatic Neuroendocrine Tumors. Therapeutic Advances in Gastroenterology, 10, 132-141.</mixed-citation></ref><ref id="hanspub.29151-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., Carnaghi, C., Buzzoni, R., et al. (2018) Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology, 106, 211-220. &lt;br&gt;https://doi.org/10.1159/000477585</mixed-citation></ref><ref id="hanspub.29151-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Grillo, F., Florio, T., Ferrau, F., et al. (2018) Emerging Multitarget Tyrosine Kinase Inhibitors in the Treatment of Neuroendocrine Neoplasms. Endocrine-Related Cancer, 25, R453-466. &lt;br&gt;https://doi.org/10.1530/ERC-17-0531</mixed-citation></ref><ref id="hanspub.29151-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Raymond, E., Dahan, L., Raoul, J.L., et al. (2011) Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 501-513. &lt;br&gt;https://doi.org/10.1056/NEJMoa1003825</mixed-citation></ref><ref id="hanspub.29151-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Chan, D.L. and Singh, S. (2018) Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinology &amp; Metabolism Clinics of North America, 47, 603-614. &lt;br&gt;https://doi.org/10.1016/j.ecl.2018.04.006</mixed-citation></ref><ref id="hanspub.29151-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Carbonero, R., Rinke, A., Valle, J.W., et al. (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology, 105, 281-294.  
&lt;br&gt;https://doi.org/10.1159/000473892</mixed-citation></ref><ref id="hanspub.29151-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Faggiano, A., lo Calzo, F., Pizza, G., et al. (2017) The Safety of Available Treatments Options for Neuroendocrine Tumors. Expert Opinion on Drug Safety, 16, 1149-1161. &lt;br&gt;https://doi.org/10.1080/14740338.2017.1354984</mixed-citation></ref></ref-list></back></article>